| meta-analysis | Q815382 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Julian Higgins | Q54818249 |
| Andrew N. Davies | Q71559068 | ||
| P2093 | author name string | J S R Gibbs | |
| K E Broadley | |||
| A-L Jennings | |||
| P2860 | cites work | Subcutaneous morphine for dyspnea in cancer patients | Q72544337 |
| Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine | Q73367318 | ||
| Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease | Q73919239 | ||
| Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 | ||
| Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease | Q33775378 | ||
| Dihydrocodeine for breathlessness in "pink puffers". | Q34991308 | ||
| Use of nebulised saline and nebulised terbutaline as an adjunct to chest physiotherapy | Q36177307 | ||
| Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer | Q38634219 | ||
| Dying from cancer: results of a national population-based investigation | Q39417667 | ||
| Dying from heart disease | Q39463890 | ||
| Cold facial stimulation reduces breathlessness induced in normal subjects | Q39537156 | ||
| Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease | Q41134837 | ||
| Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease | Q41679532 | ||
| Effects of morphine on ventilatory response to exercise | Q41738973 | ||
| Effects of nebulized morphine sulfate on the exercise tolerance of the ventilatory limited COPD patient | Q46725811 | ||
| Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. | Q51115445 | ||
| The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. | Q53575011 | ||
| Breathlessness, Alcohol, and Opiates | Q58864876 | ||
| Effects of Dihydrocodeine, Alcohol, and Caffeine on Breathlessness and Exercise Tolerance in Patients with Chronic Obstructive Lung Disease and Normal Blood Gases | Q58864889 | ||
| Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome | Q67841347 | ||
| Low-dose nebulized morphine does not improve exercise in interstitial lung disease | Q70785212 | ||
| Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure | Q71975708 | ||
| A random-effects regression model for meta-analysis | Q72228939 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | opioid | Q427523 |
| systematic review | Q1504425 | ||
| P304 | page(s) | 939-944 | |
| P577 | publication date | 2002-11-01 | |
| P1433 | published in | Thorax | Q7796158 |
| P1476 | title | A systematic review of the use of opioids in the management of dyspnoea | |
| P478 | volume | 57 |
| Q53123165 | 'To die with dignity': an update on Palliative Care. |
| Q47125009 | A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion And Morphine Sulfate (BEAMS) study |
| Q43538185 | A randomized crossover clinical trial to evaluate the efficacy of oral transmucosal fentanyl citrate in the treatment of dyspnea on exertion in patients with advanced cancer |
| Q35596067 | Academic detailing of general practitioners by a respiratory physician for diagnosis and management of refractory breathlessness: a randomised pilot study |
| Q64986649 | Activity-related dyspnea in chronic obstructive pulmonary disease: physical and psychological consequences, unmet needs, and future directions. |
| Q26777611 | Advanced Chronic Obstructive Pulmonary Disease: Innovative and Integrated Management Approaches |
| Q38701066 | Adverse cardiac events associated with incident opioid drug use among older adults with COPD. |
| Q47744249 | Aerosol furosemide for dyspnea: Controlled delivery does not improve effectiveness |
| Q33766956 | An integrative review of systematic reviews related to the management of breathlessness in respiratory illnesses |
| Q37973284 | Antimicrobial use at the end of life among hospitalized patients with advanced cancer |
| Q41443211 | Attitudes toward opioids for refractory dyspnea in COPD among Dutch chest physicians |
| Q44954511 | Attitudes towards patient care at the end of life. A survey of directors of neurological departments |
| Q98291626 | Breathlessness and opioid prescribing in COPD in general practice: a cross-sectional, observational study |
| Q36515444 | Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomized placebo-controlled URCC CCOP study. |
| Q35604997 | Can variability in the effect of opioids on refractory breathlessness be explained by genetic factors? |
| Q39246764 | Continuous subcutaneous infusion of compound oxycodone for the relief of dyspnea in patients with terminally ill cancer: a retrospective study |
| Q37008454 | Control and sensation of breathing during cycling exercise in hypoxia under naloxone: a randomised controlled crossover trial |
| Q33717352 | Degree of dyspnoea at admission and discharge in patients with heart failure and respiratory diseases. |
| Q37120940 | Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial |
| Q34198033 | Distinguishing adult-onset asthma from COPD: a review and a new approach |
| Q41139914 | Do community hospice programmes reduce hospitalisation rate in patients with advanced chronic obstructive pulmonary disease? |
| Q39209938 | Doctors' attitudes towards prescribing opioids for refractory dyspnoea: a single-centred study |
| Q39188413 | Does nebulized fentanyl relieve dyspnea during exercise in healthy man? |
| Q39306004 | Does palliative home oxygen improve dyspnoea? A consecutive cohort study |
| Q47104056 | Dosimetrically administered nebulized morphine for breathlessness in very severe chronic obstructive pulmonary disease: a randomized, controlled trial |
| Q24187632 | Drug treatments for breathlessness in end-stage cystic fibrosis |
| Q38580997 | Dying With Dyspnea in the Hospital |
| Q46379195 | Dyspnea and morphine aerosols in the palliative care of lung cancer |
| Q26822728 | Dyspnea review for the palliative care professional: treatment goals and therapeutic options |
| Q39962693 | Dyspnoea associated with anxiety--symptomatic therapy with opioids in combination with lorazepam and its effect on ventilation in palliative care patients |
| Q37931374 | EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force |
| Q46832663 | EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives |
| Q42069728 | Effect of nebulized morphine on dyspnea of mustard gas-exposed patients: a double-blind randomized clinical trial study |
| Q24628047 | Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial |
| Q38388888 | Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review |
| Q36859399 | End of life care in chronic obstructive pulmonary disease: in search of a good death |
| Q57653194 | End-of-Life Care |
| Q43256112 | End-of-life care for patients with COPD in the community setting |
| Q38944016 | End-of-life care in patients with advanced lung cancer |
| Q39340609 | Ethical and practical issues with opioids in life-limiting illness |
| Q45930729 | Evaluation of diagnostic and treatment approaches towards acute dyspnea in a palliative care setting among medical students at the University of Vienna. |
| Q37796552 | Evidence-Based Approaches to Other Symptoms in Advanced Cancer |
| Q42092259 | Evidence-based intervention for chronic refractory breathlessness: practical therapies that make a difference |
| Q36747257 | Exercise therapy in the management of dyspnea in patients with cancer |
| Q48907927 | Extending palliative care to patients with respiratory disease |
| Q33837340 | Factors associated with opioid dispensation for patients with COPD and lung cancer in the last year of life: A retrospective analysis |
| Q34582390 | Gender differences in the effect of urge-to-cough and dyspnea on perception of pain in healthy adults |
| Q22299313 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease |
| Q36892306 | Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group |
| Q28394028 | Guidelines for the diagnosis and treatment of malignant pleural mesothelioma |
| Q37228008 | High-flow oxygen and bilevel positive airway pressure for persistent dyspnea in patients with advanced cancer: a phase II randomized trial |
| Q38807604 | Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial |
| Q92524797 | Implications of the Parenteral Opioid Shortage for Prescription Patterns and Pain Control Among Hospitalized Patients With Cancer Referred to Palliative Care |
| Q37241554 | Inadequate Palliative Care in Chronic Lung Disease. An Issue of Health Care Inequality. |
| Q36410205 | Incident opioid drug use among older adults with chronic obstructive pulmonary disease: a population-based cohort study |
| Q30427793 | Integrating palliative care with intensive care for critically ill patients with lung cancer |
| Q34397960 | Interventions for alleviating cancer-related dyspnea: a systematic review and meta-analysis |
| Q58755045 | Intranasal fentanyl for respiratory distress in children and adolescents with life-limiting conditions |
| Q45885479 | Last three days of life in the hospital: a comparison of symptoms, signs and treatments in the young old and the oldest old patients using the Resident assessment instrument for palliative care. |
| Q29010615 | Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis |
| Q44604342 | Lung transplantation assessment in a patient with COPD: a case study |
| Q34529777 | Management of chronic obstructive pulmonary disease beyond the lungs |
| Q97570227 | Management of dyspnea in palliative care |
| Q37691364 | Management of dyspnea in patients with chronic obstructive pulmonary disease |
| Q37691366 | Management of refractory breathlessness in patients with advanced cancer |
| Q47941120 | Management of refractory breathlessness with morphine in patients with chronic obstructive pulmonary disease |
| Q88007895 | Managing breathlessness in advanced disease |
| Q38800285 | Managing breathlessness: a palliative care approach |
| Q30401937 | Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline |
| Q83413712 | Mechanisms of activity-related breathlessness in healthy human pregnancy |
| Q98290066 | Morphine in the Setting of Acute Heart Failure: Do the Risks Outweigh the Benefits? |
| Q46691073 | Morphine in the management of dyspnoea in ALS. A pilot study |
| Q38197148 | Nebulised furosemide in the palliation of dyspnoea in cancer: a systematic review |
| Q36102518 | Nebulized morphine for relief of dyspnea due to chronic lung disease |
| Q57360554 | Need for Mechanistically Focused Research of Global Systemic Interventions in Palliative Care |
| Q37236718 | Noninvasive ventilation as ceiling of therapy in end-stage chronic obstructive pulmonary disease. |
| Q37997540 | Nonpharmacological interventions for managing respiratory symptoms in lung cancer |
| Q44349768 | Opioid Prescription Trends Among Patients With Cancer Referred to Outpatient Palliative Care Over a 6-Year Period |
| Q90471957 | Opioid drug use in emergency and adverse outcomes among patients with chronic obstructive pulmonary disease: a multicenter observational study |
| Q38052153 | Opioid effect on lungs |
| Q30576033 | Opioid therapy for refractory dyspnea in patients with advanced chronic obstructive pulmonary disease: patients' experiences and outcomes |
| Q38170325 | Opioids for chronic refractory breathlessness: right patient, right route? |
| Q38873648 | Opioids for management of episodic breathlessness or dyspnea in patients with advanced disease |
| Q38095143 | Opioids for refractory dyspnea |
| Q35829152 | Opioids for the Management of Dyspnea in Cancer Patients: Evidence of the Last 15 Years--A Systematic Review |
| Q26766233 | Opioids: an unexplored option for treatment of dyspnea in IPF |
| Q38032796 | Palliation of dyspnea in pediatrics |
| Q89546890 | Palliative Care and the Management of Common Distressing Symptoms in Advanced Cancer: Pain, Breathlessness, Nausea and Vomiting, and Fatigue |
| Q45326612 | Palliative Care for Advanced Heart Failure in a Department of Veterans Affairs Regional Hospice Program: Patient Selection, a Treatment Protocol, and Clinical Course |
| Q54378724 | Palliative Care in Lung Cancer. |
| Q22306344 | Palliative Care in the Treatment of Advanced Heart Failure |
| Q38672357 | Palliative Pharmacotherapy: State-of-the-Art Management of Symptoms in Patients With Cancer |
| Q37960814 | Palliative care concepts in respiratory disease |
| Q36290481 | Palliative care for breathless patients in the community |
| Q39387989 | Palliative care for people with heart failure: summary of current evidence and future direction |
| Q39224190 | Palliative care for people with non-malignant lung disease: summary of current evidence and future direction. |
| Q50803732 | Palliative care in chronic obstructive pulmonary disease: a review for clinicians. |
| Q34171921 | Palliative care in lung cancer |
| Q79073394 | Palliative care in non-oncologic patients |
| Q33672292 | Palliative care in the ICU: relief of pain, dyspnea, and thirst--a report from the IPAL-ICU Advisory Board |
| Q87302895 | Palliative care of chronic progressive lung disease |
| Q88007913 | Palliative care of chronic progressive lung disease |
| Q35750714 | Palliative care provision for patients with chronic obstructive pulmonary disease |
| Q38631088 | Palliative drug treatments for breathlessness in cystic fibrosis. |
| Q37018836 | Palliative management of refractory dyspnea in COPD. |
| Q56979009 | Palliative use of non-invasive ventilation in end-of-life patients with solid tumours: a randomised feasibility trial |
| Q37151821 | Patients with End-stage Interstitial Lung Disease may have More Problems with Dyspnea than End-stage Lung Cancer Patients |
| Q30517901 | Perspectives of patients, family caregivers and physicians about the use of opioids for refractory dyspnea in advanced chronic obstructive pulmonary disease |
| Q47964378 | Pharmacological Management of People Living with End-Stage Chronic Obstructive Pulmonary Disease. |
| Q38817813 | Pharmacological management of breathlessness in COPD: recent advances and hopes for the future |
| Q57360949 | Pharmacological management of breathlessness in advanced disease |
| Q43061646 | Pharmacological treatment of refractory breathlessness |
| Q36843717 | Pharmacotherapies for COPD. |
| Q42919187 | Potential Opioid-Sparing Effect of Regular Benzodiazepines in Dyspnea: Longer Duration of Studies Needed |
| Q37376741 | Prescription of opioids for breathlessness in end-stage COPD: a national population-based study |
| Q35905977 | Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea |
| Q41786446 | Recent advances in the management of breathlessness |
| Q48802071 | Refractory breathlessness: oxygen or room air? |
| Q90659946 | Respiratory events associated with concomitant opioid and sedative use among Medicare beneficiaries with chronic obstructive pulmonary disease |
| Q34247647 | Respiratory medicine. |
| Q48539031 | Responding to persistent requests for assistance in dying: a phenomenological inquiry |
| Q37532386 | Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study |
| Q47150721 | Scientific Opinion on the risks for public health related to the presence of opium alkaloids in poppy seeds |
| Q24203818 | Self management interventions for breathlessness in adult cancer patients |
| Q36154887 | Statement on home care for patients with respiratory disorders |
| Q30110836 | Studies on electron transfer between mercury electrode and hemoprotein |
| Q37516685 | Study protocol: a phase III randomised, double-blind, parallel arm, stratified, block randomised, placebo-controlled trial investigating the clinical effect and cost-effectiveness of sertraline for the palliative relief of breathlessness in people w |
| Q38155857 | Supportive and palliative care for lung cancer patients. |
| Q38602725 | Symptom-based management of the idiopathic interstitial pneumonia. |
| Q43076007 | Symptomatic treatment of dyspnea in advanced cancer patients : A narrative review of the current literature |
| Q58036478 | The effect of the Shipman murders on clinician attitudes to prescribing opiates for dyspnoea in end-stage chronic obstructive pulmonary disease in England |
| Q44339535 | The effects of opioid receptor blockade on experimental panic provocation with CO2. |
| Q37072351 | The etiology and management of intractable breathlessness in patients with advanced cancer: a systematic review of pharmacological therapy |
| Q37032302 | The longitudinal pattern of response when morphine is used to treat chronic refractory dyspnea |
| Q33316118 | The management of dyspnea in cancer patients: a systematic review. |
| Q43999316 | The need to address increasing opioid use in elderly COPD patients |
| Q38098479 | The pharmacological approach to the elderly COPD patient |
| Q37263363 | The symptomatic relief of dyspnea |
| Q45958882 | Treatment of Acute Dyspnea with Morphine to Avert Respiratory Failure. |
| Q47791471 | Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia |
| Q42423756 | Unfair treatment. |
| Q35528427 | Using laboratory models to test treatment: morphine reduces dyspnea and hypercapnic ventilatory response |
| Q41831003 | Using opioids to treat dyspnea in advanced COPD: attitudes and experiences of family physicians and respiratory therapists. |
| Q45987816 | What can we learn from simulation-based training to improve skills for end-of-life care? Insights from a national project in Israel. |
| Q50795103 | [Alveolar epithelial cell injury as an etiopathogenic factor in pulmonary fibrosis]. |
| Q80414925 | [Palliative care of dyspnea at the end of life] |
| Q58659931 | [Symptom control and ethics in final stages of COPD] |
Search more.